GlassScriptPhysician profile
Bradley C Drury
NPI 1366436677
$3,871.48
in general payments reported to CMS, 2019-2025
38 companies · $73.65 in 2025
The $73.65 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $340 · 2021: $68.35 · 2022: $92.44 · 2023: $1,410 · 2024: $550 · 2025: $73.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $388.44 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $313.72 | 2019-2024 | Breztri, Farxiga, Fasenra |
| Amgen INC. | $267.64 | 2019-2024 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $237.66 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $234.24 | 2022-2024 | Ubrelvy, Linzess, Viberzi |
| Allergan, INC. | $222.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.25 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $183.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $169.13 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.32 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $148.11 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $136.93 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $104.58 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $104.15 | 2019-2023 | Veozah |
| Sumitomo Pharma America, INC. | $89.18 | 2023-2024 | Gemtesa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Drury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.